Zealand Pharma A/S (ZLDPF) Projected to Post Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF) is expected to be releasing its results before the market opens on Thursday, August 13th. Analysts expect Zealand Pharma A/S to announce earnings of $0.1431 per share and revenue of $692.1160 million for the quarter.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock opened at $50.50 on Tuesday. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of 3.75 and a beta of 0.88. The stock’s fifty day moving average is $45.44 and its two-hundred day moving average is $49.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17.

Analysts Set New Price Targets

Several research firms recently commented on ZLDPF. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.